Is Bluebird Bio a takeover target?
Sarah Cherry
Updated on March 30, 2026
Similarly one may ask, who will acquire bluebird bio?
Under the terms of the agreement, Resilience will acquire bluebird bio's research triangle (bRT) manufacturing facility in North Carolina, US, retaining all of the technical staff and administrators currently employed at the site.
Likewise, is bluebird bio a buy? bluebird bio has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on 2 buy ratings, 17 hold ratings, and no sell ratings.
Subsequently, one may also ask, what is wrong with bluebird bio?
Bluebird said that a patient treated with the gene therapy, known as eli-cel, had developed myelodysplastic syndrome, a type of cancer. “Our hearts go out to this patient and his family, who are dealing with a challenging diagnosis,†the company's CEO, Nick Leschly, said in a statement.
Will bluebird bio survive?
Bluebird's gene therapies have somewhat proven themselves in previous clinical studies. bb1111 completely eliminated the occurrence of VOCs after infusion in SCD patients.
Related Question Answers
Should I invest in Bluebird?
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Bluebird Bio is 'Strong Buy'.Is Bluebird Bio a public company?
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.Why is blue stock dropping?
Bluebird Stock Crashes To 7-Year Low After FDA Pauses Gene Therapy Test. Bluebird Bio said Monday the FDA paused one of its gene therapy studies due to safety concerns, and BLUE stock collapsed.Is Bluebird Bio profitable?
Earnings vs Industry: BLUE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).Is BLUE a buy stock?
Out of 10 analysts, 2 (20%) are recommending BLUE as a Strong Buy, 1 (10%) are recommending BLUE as a Buy, 7 (70%) are recommending BLUE as a Hold, 0 (0%) are recommending BLUE as a Sell, and 0 (0%) are recommending BLUE as a Strong Sell. What is BLUE's earnings growth forecast for 2021-2023?Where is bluebird bio?
Cambridge, Massachusetts, U.S. bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer.Will bluebird bio bounce back?
After 5-month hiatus, bluebird bio's Zynteglo bounces back in Europe with all-clear from safety group. With a positive safety ruling in hand, bluebird bio has surmounted another hurdle and will once again forge ahead with the European rollout of its beta-thalassemia gene therapy Zynteglo.Is Zynteglo approved in the US?
Zynteglo isn't yet approved in the U.S., though the company says it aims to submit its rolling Biologics License Application in beta-thalassemia by the middle of the year. The FDA has blessed Zynteglo with both an Orphan Drug tag and Breakthrough Therapy designation in TDT.How much is Zynteglo?
set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe earlier this month to to treat patients 12 years and older with transfusion-dependent β-thalassaemia (TDT), who have no matching donor for a stem cell transplant.What gene therapies are approved?
Approved Cellular and Gene Therapy Products- ABECMA (idecabtagene vicleucel)
- ALLOCORD (HPC, Cord Blood)
- BREYANZI.
- CLEVECORD (HPC Cord Blood)
- Ducord, HPC Cord Blood.
- GINTUIT (Allogeneic Cultured Keratinocytes and Fibroblasts in Bovine Collagen)
- HEMACORD (HPC, cord blood)
- HPC, Cord Blood.
